Research programme: thorium-227 radiolabelled antibodies - Bayer/Progenics

Drug Profile

Research programme: thorium-227 radiolabelled antibodies - Bayer/Progenics

Alternative Names: 1095 - Bayer/Progenics; HER2 TTC; PSMA targeted thorium-227 conjugate; PSMA TTC; PSMA-ADC; Trastuzumab-Th-227

Latest Information Update: 05 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer
  • Class Antibodies; Antineoplastics; Immunoconjugates; Radiopharmaceuticals
  • Mechanism of Action ERBB 4 receptor antagonists; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Gastric cancer; Lung cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 09 May 2018 Bayer plans a phase I trial for PSMA-targeted thorium-227 conjugate in Prostate cancer by year end 2018
  • 01 Apr 2017 Preclinical trials in Gastric cancer in Germany (Parenteral)
  • 01 Apr 2017 Preclinical trials in Lung cancer in Germany (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top